LoginSignup
CRT

CRISM'

Stock
Stock
ISIN: VGG042401262
Ticker: CRTX
VGG042401262
CRTX

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

 

$3.647

CHART BY

Frequently asked questions

What is CRISM''s market capitalization?

The market capitalization of CRISM' is 1.87M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for CRISM'?

CRISM''s Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.0203. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for CRISM''s stock?

Currently, 1 analysts cover CRISM''s stock, with a consensus target price of 1.581. Analyst ratings provide insights into the stock's expected performance.

What is the EBITDA for CRISM'?

CRISM''s Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -889.00K. EBITDA measures the company's overall financial performance.

What is the free cash flow of CRISM'?

CRISM' has a free cash flow of -933.00K. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the free float of CRISM''s shares?

The free float of CRISM' is 8.66M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
1.87M
EPS (TTM) 
-$0.0203
Free Float 
8.66M
EBITDA (TTM) 
-889.00K
Free Cashflow (TTM) 
-933.00K

Pricing

52W span
$0.0643$0.394

Analyst Ratings

The price target is 1.581 and the stock is covered by 1 analysts.

Buy

1

Hold

0

Sell

0

Information

CRISM Therapeutics Corp. is a biotechnology company, which engages in the development of cancer treatment drugs for solid tumors. It offers ChemoSeed product which is a biodegradable drug delivery technology designed for the delivery of chemotherapy directly into cancer tissue. Its services include formulation and consultancy. It operates through the Head Office and Scientific Research segments. The Head Office segment focuses on the administrative in nature and undertaken from the United Kingdom. The Scientific Research segment relates to the work being undertaken on its key research program, ChemoSeed for glioma, and any income associated with it in the form of grants or consultancy. The company was founded in March 2016 and is headquartered in Road Town, British Virgin Islands.

Industries
Miscellaneous Commercial Services
Sector
Health Care

Identifier

ISIN
VGG042401262
Primary Ticker
CRTX
Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin